Last updated: November 8, 2021
Sponsor: Imperial College London
Overall Status: Active - Recruiting
Phase
3
Condition
Liver Disorders
Hepatitis
Treatment
N/AClinical Study ID
NCT03069300
14SM2383
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Aged 18 years or older
- Clinical alcoholic hepatitis:
- Serum bilirubin >80umol/L
- History of alcohol excess (>80g/day male, >60g/day female)
- Less than 4 weeks since admission to hospital
- Maddrey's discriminant function (DF) >32
- Informed consent
Exclusion
Exclusion Criteria:
- Alcohol abstinence of >6 weeks prior to randomisation
- Duration of jaundice >3 months
- Other causes of liver disease including:
- Evidence of viral hepatitis (hepatitis B or C)
- Biliary obstruction
- Hepatocellular carcinoma
- Evidence of current malignancy (except non-melanotic skin cancer)
- Previous entry into the study
- Patients with known hypersensitivity or previous reactions to NAC
- Pregnant or lactating women
Study Design
Total Participants: 42
Study Start date:
October 01, 2015
Estimated Completion Date:
June 01, 2025
Study Description
Connect with a study center
St Mary's Hospital, Imperial College
London, W2 1NY
United KingdomActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.